Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3193-3201

  Ebert, W ^a   Muley, Th ^a   Herb, K P ^a   Schmidt Gayk, H ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Limbach Laboratory   (Germany)

Author keywords

Bone markers; Bone metastasis; Bone scintigraphy; Lung carcinoma

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; PYRIDINOLINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE DEVELOPMENT; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; INTERMETHOD COMPARISON; LUNG CARCINOMA; MALE; OSTEOLYSIS; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; ROC CURVE; SERUM; URINALYSIS;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 6344284449     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Napoli LD, Hansen HH and Muggia FM: The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology 108: 17-21, 1973.
2. Abrams HL, Spiro R and Goldstein N: Metastasis in carcinomas: analysis of 1000 autopsied cases. Cancer 3: 74-85, 1950.
3. McNeil B: Value of bone scanning in neoplastic disease. Semin Nucl Med 14: 277-286, 1984.
4. Meijer WG, Van der Veer E and Willemse PHB: Biochemical parameters of bone metabolism in bone metastases of solid tumors (review). Oncology Reports 5: 5-21, 1998.
5. Aruga A, Koizumi M, Hotta R, Takahashi S and Ogata E: Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76: 760-764, 1997.
6. Kobayashi T, Gabazza EC, Taguchi O, Risteli J, Risteli L, Kobayashi H, Yasui H, Yuda H, Sakai T, Kaneda M and Adachi Y: Type I collagen metabolites as tumor markers in patients with lung carcinoma. Cancer 85: 1951-1957, 1999.
7. Izumi M, Nakanishi Y, Takayama K, Kimotsuki K, Inoue K, Wataya H, Minami T and Hara N: Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer 91: 1487-1493, 2001.
8. Mountain CF: Revisions in the international item for staging lung cancer. Chest 111: 1710-1717, 1997.
9. World Health Organization: Histological Classification of Lung Tumors. WHO, Geneva, 1981.
10. Black D, Duncan A and Robins PR: Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169: 197-203, 1988.
11. Kruskal WH: A nonparametric test for the several sampling problems. Ann Math Stat 23: 525-540, 1952.
12. Mann HB and Whitney PR: On a test whether one of two random variables is stochastically larger than the other. Ann Math Stat 18: 50-60, 1974.
13. Tubiana-Hulin M: Incidence, prevalence and distribution of bone metastases. Bone 12 (suppl. 1): 9-10, 1991.
14. Liotta LA: Tumor invasion and metastasis: role of the extracellular matrix. Cancer Res 46: 1-7, 1986.
15. Terranova, PV, Hujanen ES and Martin G: Basement membrane and the invasion activity of metastatic tumor cells. J Natl Cancer Inst 77: 311-316, 1986.
16. Ebert W, Brömmer H, Schapöhler B and Muley T: Elevated serum levels of ICTP do not prove metastases in small cell lung cancer. In: (Klapdor R, ed) Current Tumor Diagnosis: Clinical Relevance, Research, Trends, W. Zuckschwerdt Munich, Bern, Vienna, New York, 1994, pp 242-245.
17. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 15: 2996-3018, 1997.
18. European Society of Medical Oncology: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol 12: 1051-1052, 2001.
19. European Society of Medical Oncology: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 12: 1049-1050, 2001.